Oppenheimer Maintains Outperform on RxSight, Raises Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on RxSight (NASDAQ:RXST) and raises the price target from $54 to $61.
February 29, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on RxSight and raises the price target from $54 to $61.
The increase in price target by a reputable analyst firm like Oppenheimer typically signals a strong bullish sentiment on the stock, suggesting a positive outlook on RxSight's performance. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100